文献速递乳腺癌

OlympiA III期试验:胚系BRCA1/2致病变异高危早期乳腺癌辅助奥拉帕利的总体生存

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
PubMed 文献 · Ann Oncol · 2022-10-10

中位随访3.5年的第二次预设期中分析显示奥拉帕利组OS显著改善(HR 0.68),IDFS和DDFS获益维持,无新安全信号。

要点

  • 中位随访3.5年,奥拉帕利组OS显著优于安慰剂组,HR 0.68(98.5%CI 0.47-0.97;P=0.009)。
  • 4年OS奥拉帕利组89.8% vs 安慰剂组86.4%(Δ3.4%,95%CI -0.1%至6.8%)。
  • 4年IDFS 82.7% vs 75.4%,4年DDFS 86.5% vs 79.1%,无新安全信号。

核心结论

  • 中位随访3.5年,gBRCA1/2致病变异相关早期乳腺癌辅助奥拉帕利较安慰剂显著改善OS,并维持IDFS和DDFS的显著改善,无新安全信号。

研究设计与样本

  • 患者在(新)辅助化疗、手术及有指征的放疗后入组,激素受体阳性者同步接受内分泌治疗。
  • 本次为预设的第二次OS期中分析,同时更新IDFS、DDFS和安全性;OS统计学显著性要求P<0.015。

主要发现

  • 奥拉帕利组相对安慰剂组OS显著改善:HR 0.68(98.5%CI 0.47-0.97;P=0.009)。
  • 4年OS奥拉帕利组89.8% vs 安慰剂组86.4%(Δ3.4%,95%CI -0.1%至6.8%)。
  • 4年IDFS奥拉帕利组82.7% vs 安慰剂组75.4%(Δ7.3%,95%CI 3.0%至11.5%)。
  • 4年DDFS奥拉帕利组86.5% vs 安慰剂组79.1%(Δ7.4%,95%CI 3.6%至11.3%)。
  • OS、IDFS、DDFS的亚组分析在主要亚组中均显示获益;未发现新安全信号,包括无新发急性髓系白血病或骨髓增生异常综合征病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. PATIENTS AND METHODS: One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. RESULTS: With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. CONCLUSION: With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022. PMID: 36228963. doi:10.1016/j.annonc.2022.09.159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。